Therapeutic Response

BRAF p.V600K status confers therapeutic sensitivity to Dabrafenib in patients with Melanoma.

Statements

Source and description
Tafinlar (dabrafenib) [product monograph]. HC. Health Canada approved dabrafenib as a monotherapy, or in combination with trametinib, for the treatment of patients with the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.